The Rise of CRISPR Diagnostics

At a high level, CRISPR diagnostics give you a programmable way to detect specific genetic targets. You design a guide RNA (gRNA) to match the sequence you care about, and CRISPR-associated enzymes—typically Cas12 or Cas13—use that guide to find it in your sample. In most workflows, this detection step is paired with an amplification stage, such as RPA or RT-RPA, to increase the amount of target material and improve sensitivity. Once the target is present in sufficient quantity, the CRISPR system activates and produces a detectable signal—either through fluorescence or a visual readout like a lateral flow strip.

The result is a fast, specific way to determine whether your target is present—without the need for complex thermal cycling or heavy lab infrastructure.

That’s the high-level view. If you want a deeper dive into how each step works—from amplification through signal detection—check out our full technical guide: How to Build an RPA-CRISPR Assay for Rapid Diagnostics.

If you’re developing a diagnostic, you’ve probably run into the same challenge: balancing sensitivity, specificity, speed, and accessibility. Traditional methods tend to force tradeoffs—PCR offers strong sensitivity and quantification but requires more infrastructure, while rapid tests are faster and simpler but can miss low-abundance targets. CRISPR gives you more flexibility in how you approach that balance. When paired with amplification methods like RPA or RT-RPA, it allows you to achieve strong sensitivity without the complexity of PCR, while keeping workflows relatively fast and flexible. And because CRISPR is programmable, you can adapt your assay more quickly as targets change—without starting from scratch.

So rather than choosing one approach over another, the real question becomes: where does each method fit best in your workflow?

Where CRISPR Diagnostics Add the Most Value

CRISPR-based diagnostics really start to stand out when speed, flexibility, and accessibility matter. If you’re working in a setting where timelines are tight, targets are evolving, or testing needs to happen outside of a traditional lab, CRISPR gives you more room to adapt. Instead of forcing you into a single workflow, it lets you design based on your specific needs, whether that’s faster turnaround, simpler deployment, or the ability to pivot quickly as things change.

• Get fast results without giving up specificity: By pairing RPA or RT-RPA with CRISPR detection, you can generate results in under an hour while still targeting highly specific genetic sequences.
• Design assays around exactly what you need to detect: The gRNA acts as a programmable component, giving you precise control over which pathogens, variants, or mutations your assay identifies.
• Adapt quickly as targets evolve: Instead of rebuilding your entire system, you can often update your assay by redesigning the gRNA—making it much easier to respond to emerging threats.
• Move testing beyond the lab: Because CRISPR-based assays don’t require complex thermal cycling, they can be used in point-of-care, field, or resource-limited environments.
• Detect multiple targets in a single workflow: With the right design, you can build multiplexed assays that give you more information from a single sample with a single test.

What You Should Keep in Mind

At the same time, it’s important to be aware of where CRISPR requires careful optimization. One of the main challenges is the potential for off-target effects. In some cases, gRNAs can tolerate small mismatches, which may lead to unintended signal generation if the assay isn’t fully optimized. For you, this means that performance depends heavily on how well your gRNA is designed and validated. Investing upfront in guide selection and validation can significantly reduce variability and improve reliability, especially as you move toward real-world use.

Where Traditional Methods Still Excel

CRISPR brings a lot of flexibility, but traditional diagnostic methods still play an important role in many workflows. In many cases, they’re still the right tool for the job.

• Exceptional sensitivity for low-abundance targets: When you need to detect very small amounts of genetic material, PCR is still the gold standard.
• Reliable quantification of viral or bacterial load: Techniques like qPCR don’t just tell you if something is present—they tell you how much is there, which is critical for many clinical and research applications.
• A clear path through regulatory and clinical workflows: With decades of validation and widespread adoption, PCR is often easier to integrate into regulated environments.
• Familiar, standardized processes across labs: Most labs are already set up to run PCR, which can simplify implementation and scaling.

CRISPR vs. Traditional Diagnostics at a Glance

So what actually goes into building a CRISPR-based diagnostic—and how do you make sure it performs reliably beyond the lab?

It starts with a few core decisions. One of the first is choosing the right CRISPR enzyme. In most cases, Cas12 is used for DNA targets, while Cas13 is better suited for RNA, including many viruses. From there, gRNA design becomes critical. Because the gRNA determines what your assay detects, even small mismatches can impact specificity, so careful design, testing, and validation are essential.

You’ll also need to think about how results are going to be read. If you’re working in a lab setting, fluorescence-based detection may make the most sense. But if your goal is point-of-care or field deployment, lateral flow formats offer a simpler, more accessible option. At the same time, real-world samples introduce their own challenges. Blood, saliva, or environmental samples can contain inhibitors or variability that affect performance, so making sure your assay works consistently across sample types is key.

As you move from early development to real-world use, the focus shifts from “does it work?” to “does it work every time?” Scaling a CRISPR diagnostic means thinking about reproducibility, manufacturability, and consistency across batches. Stability also becomes increasingly important, especially if your assay needs to be stored, transported, or used outside of controlled lab environments, where lyophilized (lyo) components can help maintain performance and stability. Variability, especially in components like gRNA, can directly impact results, which makes quality control and standardized processes increasingly important. You’ll also need to consider validation and regulatory requirements, depending on where and how your diagnostic will be used.

Planning for these factors early can save significant time later, helping you build a diagnostic that not only works in development, but holds up in real-world conditions.

Developing a CRISPR-based diagnostic requires more than a strong concept—it depends on how reliably each component performs within your workflow. From amplification through detection, consistency and reproducibility are critical to achieving results you can trust at scale. Synthego supports your development process by providing integrated solutions across both target amplification and CRISPR detection, helping you reduce variability so your assay performs more consistently from development through deployment.

Why choose Synthego?

• Integrated, lyophilized amplification and detection solutions: Synthego’s lyophilized RPA and RT-RPA kits enable rapid, isothermal amplification of DNA and RNA targets, improving sensitivity upstream of CRISPR detection while simplifying storage, transport, and workflow integration.
• High-quality synthetic guide RNAs: Designed for precision and consistency, Synthego’s gRNAs support reliable target recognition and reduce variability across experiments and batches.
• Scalable manufacturing from research to deployment: Whether you’re optimizing an assay or preparing for larger-scale production, Synthego’s synthesis platforms support reproducibility at every stage.
• Custom optimization aligned to your workflow: Synthego offers tailored support across both gRNA design and RPA/RT-RPA kit configuration, helping you optimize performance based on your target, sample type, and deployment environment.
• Expert support across your workflow: From early assay design through validation and scale-up, Synthego provides guidance to help you troubleshoot and refine your system efficiently.

By providing reagents and customizable solutions for both amplification (RPA/RT-RPA) and CRISPR detection (gRNA & nucleases), Synthego helps you build a more cohesive and reliable workflow—so you can focus on performance, validation, and scaling rather than managing variability across components.

Two platform technologies officially put CRISPR diagnostics on the map: SHERLOCK (built on the Cas13 enzyme) and DETECTR (built on Cas12). While these started as fascinating laboratory breakthroughs, they quickly evolved into critical tools for solving complex, real-world problems.

By combining the programmable precision of CRISPR with rapid isothermal amplification methods like RPA, these platforms are making an impact across a growing footprint of applications. If you are looking to design your own workflow, you can explore our complete guide on how to build an RPA-CRISPR diagnostic assay from scratch.

Pandemic Response & Viral Detection

The true crucible moment for CRISPR diagnostics began during the 2015–2016 Zika crisis. Tracking an outbreak in real-time across resource-limited regions is notoriously difficult, but researchers demonstrated that paper-based CRISPR/Cas9 assays could identify viral RNA directly in the field—a breakthrough detailed in our comprehensive look at what CRISPR can do to help in the fight against the Zika virus. This proof-of-concept directly paved the way for the Cas13-powered SHERLOCK platform in 2017, which leveraged collateral cleavage to hunt down viral RNA with staggering, attomolar precision on simple paper strips.

The technology made history again in 2020, becoming the first-ever CRISPR-based tech to receive an FDA Emergency Use Authorization (EUA) for SARS-CoV-2 detection. We sat down with SHERLOCK co-inventors Omar Abudayyeh and Jonathan Gootenberg to discuss the mechanics behind this milestone—you can listen to the conversation and explore the technology's roots in our post on SHERLOCK CRISPR diagnostics and the next generation of testing.

As viral variants emerged, CRISPR's programmable nature allowed assays to adapt rapidly. You can look back at our technical breakdowns of early CRISPR coronavirus detection strategies and check out the optimization protocols we outlined for high-throughput STOPCovid CRISPR diagnostics to see how flexible these platforms can be during an active crisis.

Oncology: Catching Cancer Earlier

The speed and sensitivity of CRISPR make it highly suitable for rapid cancer monitoring. Where traditional PCR requires specialized lab personnel and next-generation sequencing (NGS) can take days or weeks, CRISPR offers a faster alternative. By pairing Cas13a with gold nanoarrays, a research team from Rutgers developed a highly sensitive diagnostic assay capable of rapidly identifying colorectal cancer biomarkers without requiring massive, expensive lab infrastructure.

Food Safety & Agriculture

Pathogens don't just threaten human health; they pose massive risks to the global food supply. We recently explored this challenge in our deep dive, Why Is Foodborne Pathogen Detection So Difficult?, examining how complex sample matrices and traditional testing bottlenecks leave supply chains vulnerable.

CRISPR-powered biosensors are opening up new possibilities to overcome these testing bottlenecks by enabling ultra-fast, accessible pathogen screening. For instance, researchers in Austria successfully used the Cas12-based DETECTR platform alongside RPA to rapidly identify a devastating fungus affecting bananas and plantains, allowing farmers to catch agricultural threats directly in the field before they destroy entire yields.

Environmental Monitoring & Beyond

CRISPR isn't even limited to tracking nucleic acids anymore. By coupling Cas12a with DNA aptamers—short, engineered DNA sequences designed to bind tightly to specific target molecules—scientists have broken past the boundaries of traditional DNA/RNA testing. A prime example is the recent development of a hybrid CRISPR biosensor used to detect aflatoxin, a dangerous toxic pollutant, directly in dairy products.